Shockwave ®S4 Catheter IVL to Treat Infrapopliteal Calcified Stenoses and/or Occlusions in CLTI Patients (LEGACY)

Peripheral Arterial Disease Clinical Trial

— LEGACY  

Official title:

Observational, Prospective, Single-arm Multicentric Study of Shockwave ®S4 Catheter IVL (Intravascular Lithotripsy) Balloon for the Treatment of Infrapopliteal Calcified Stenoses and/or Occlusions in Patients With Critical Limb Ischaemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05755412
• Other study ID #: IVL012022
• Status: Recruiting
• Start date: March 14, 2023
• Est. completion date: March 2025

Study information

• Verified date: November 2023
• Source: EndoCore Lab s.r.l.
• Contact: Gabriele Morselli, PharmD
• Phone: +39 3499105666
• Email: gabriele.morselli[@]endocorelab.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study will evaluate the safety and efficacy of Peripheral Intravascular Lithotripsy system with Shockwave S4 catheter® for the treatment of de novo, re-stenosis or re-occlusive,calcified chronic total occlusion (CTOs) lesions in patients with Critical Limb Threatening Ischemia (CLTI).

Description:

The present study is designed as a multicentre, prospective, single-arm, observational study. All eligible subjects for undergoing intervention with Shockwave S4 catheter® Peripheral Intravascular Lithotripsy (IVL) at sites participating in the study will be considered for enrolment and will be asked to give consent prior to participating. Subjects will be considered enrolled in the study at the time written informed consent is given to the use of their personal data. Once patients are enrolled, their demographics, medical history, disease-relevant conditions, treatment details and outcomes will be collected for up to 12 months from the procedure. The study will collect information about the medical care patients receive during their planned procedure. No additional testing or procedures will be done. The procedure with Shockwave S4 catheter® Peripheral Intravascular Lithotripsy (IVL) will be performed as per the current instructions for use. After discharge all patients will attend clinic visits at 30 days (±14 days), 6 months (±30 days),12 months (±30 days).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 32
• Est. completion date: March 2025
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age =18 years
• Patient has signed an approved informed consent form
• Patient with Critical Limb Ischaemia, Rutherford category 4 (ischaemic rest pain), 5(minor tissue loss) or 6 (major tissue loss)
• Patient with Stenotic (>50% luminal loss) or occluded infrapopliteal artery, including the tibiofibular trunk, the anterior tibial artery, the posterior tibial artery and the peroneal artery
• The vascular lesion length will be no longer than 150 mm.
• Patient with no significant disease at the inflow: common iliac, external iliac, superficial femoral and popliteal artery on the ipsilateral side prior to enrollment, and patient with no significant disease at the outflow - runoff to ankle level: plantar for posterior tibial, pedal for anterior tibial, anterior and posterior perforant branches for peroneal vessels or previous successful revascularization of the disease segments (inflow-outflow)
• Live expectancy > 1 year.
• Presence at least =1 filling pedal vessel on the target limb.

Exclusion Criteria:

• Subject pregnant or planning to become pregnant during the study
• Subject no able to perform the follow up or other factors making clinical follow-up difficult
• Acute or Subacute limb ischaemia which requires thrombolysis as first treatment modality or previous thrombolytic therapy in the last 48-72 hours.
• Known allergy to concomitant medication, antiplatelet anti-coagulant or thrombolytic medication
• Poor inflow due to ipsilateral stenoses or occlusions of the iliac or femoropopliteal arteries
• Significant stenoses (> 50%) distal to the target lesion that might require revascularization or impede run-off
• Desert foot condition. No Patent foot main arteries
• Subject enrolled in another investigational study that has not reached its primary endpoint

Related Conditions & MeSH terms

• Ischemia
• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Locations

Country	Name	City	State
Italy	Casa di Cura Abano Terme	Abano Terme	Padova
Italy	Ospedale Pederzoli	Peschiera Del Garda	Veneto
Italy	Arcispedale Santa Maria Nuova	Reggio Emilia
Italy	I.R.C.C.S. MultiMedica	Sesto San Giovanni	Milano

Sponsors (2)

Lead Sponsor	Collaborator
EndoCore Lab s.r.l.	Fondazione Italiana Vascolare

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite of Acute Gain Index and freedom from clinically driven target lesion revascularization (CD-TLR) through 6 months post procedure	Acute Gain Index defined as the Acute Gain (difference between the vessel diameter before and after IVL) divided by the Reference Vessel Diameter; CD-TLR defined as as repeat percutaneous intervention or surgical bypass graft to treat an angiographic significant restenosis (>50%) at the level of the treated lesion ±10 mm (proximally and/or distally) in the presence of at least 1 of the following criteria: recurrence of pain in the foot at rest that increases in the supine position; recurrence of pedal ulceration, evidence of halted healing; appearance of a new foot lesion; target vessel occlusion (by either angiography or DUS).	30 days, 6 months
Secondary	Composite of Freedom from device and procedure-related death and freedom from target limb major amputation and clinically-driven and mechanical target lesion revascularization (CD-MTLR)	Composite of Freedom from device and procedure-related death through 30 days post-procedure and freedom from target limb major amputation and clinically-driven and mechanical target lesion revascularization (CD-MTLR) through 6 months post-procedure	30 days, 6 months
Secondary	Late Lumen Loss Index	Late Lumen Loss defined as Late Lumen Loss divided by Acute Lumen Gain	6 months
Secondary	Rutherford class shift	Assess clinical improvement based on Rutherford class changes at 1, 6, 12 months, compared to baseline	Baseline, 30 days, 6 months, 12 months
Secondary	Amputation rate	defined as rate of minor and major amputations	30 days, 6 months, 12 months
Secondary	CD-TLR	Clinically-driven target lesion revascularization (CD-TLR) is defined as any reintervention within the target lesion due to symptoms	30 days, 6 months
Secondary	Technical success	Technical success, defined as achievement of a final in-lesion residual diameter stenosis of =50% (as determined by the angiographic core lab), using the Shockwave S4 catheter, without a device malfunction after wire passage through the lesion.	Day 1
Secondary	Clinical Success	Clinical success (per subject) defined as technical success without the occurrence of major adverse events during the procedures (as determined by the angiographic core lab)	Day 1
Secondary	Procedural Success	Procedural success defined as lesion success without the occurrence of major adverse events during the procedure	Day 1
Secondary	Ankle-brachial index (ABI) or trans-cutaneous oximetry (TcPO2) improvements	Assess ABI or TcPO2 improvements	Baseline,30 days, 6 months, 12 months
Secondary	Major adverse event (MAE) rates	Major adverse event (MAE) rates, defined as the first occurrence of any of the following: death from any cause, major amputation (above-the-ankle) of the target limb and target lesion revascularization (TLR), through 12 months	30 days, 6 months, 12 months